You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Idh Mutation

Showing 1 - 25 of 2,728
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Correlation Between SPECT/CT and IDH Mutation in Brain Glioma

Not yet recruiting
  • Brain Glioma
    • (no location specified)
    Oct 23, 2022

    Single Photon Emission Computed Tomography/Computed Tomography

    Not yet recruiting
    • Brain Glioma
    • SPECT with pentavalent 99mTc DMSA
    • (no location specified)
    Oct 23, 2022

    How Habitats Created by MRI Can Predict IDH Mutation Status and

    Recruiting
    • High-grade Glioma
      • Chongqing, Chongqing, China
        Department of Radiology, Daping Hospital of Army Medical Univers
      Aug 1, 2022

      Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

      Not yet recruiting
      • Glioma
      • +3 more
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      Jul 22, 2022

      Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

      Recruiting
      • Recurrent IDH1/2 Mutated Glioma
      • Paris, France
        Pitie Salpetriere Hospital
      Aug 29, 2022

      IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

      Recruiting
      • IDH Mutation
      • +4 more
      • Chicago, Illinois
        University of Chicago Medical Center
      Nov 12, 2021

      Space Occupying Lesions of the Brain

      Recruiting
      • Brain Tumor
      • +2 more
      • MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
      • Bern, Switzerland
        Institute for Diagnostic and Interventional Neuroradiology, Univ
      Jan 26, 2023

      Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

      Not yet recruiting
      • Cholangiocarcinoma Non-resectable
      • Cholangiocarcinoma Metastatic
      • (no location specified)
      Oct 10, 2023

      Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

      Recruiting
      • Low-grade Glioma
      • +4 more
      • Boston, Massachusetts
        Massachusetts General Hospital
      Oct 19, 2022

      Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

      Not yet recruiting
      • Cholangiocarcinoma With IDH1 Mutation
      • Solid Tumors With IDH1 Mutation
      • AB-218 capsule
      • Beijing, Beijing, China
        Peking Union Medical College Hospital, Chinese Academy of Medica
      Apr 2, 2023

      Glioma, Cholangiocarcinoma, Solid Tumor Trial in Toronto (Olaparib, Durvalumab)

      Recruiting
      • Glioma
      • +3 more
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      Nov 29, 2021

      Glioma, IDH Mutation Trial (BAY 2402234)

      Withdrawn
      • Glioma
      • IDH Mutation
      • BAY 2402234
      • (no location specified)
      Dec 17, 2021

      Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia

      Recruiting
      • Acute Myeloid Leukemia
      • +6 more
      • Biospecimen Collection
      • +2 more
      • Orange, California
      • +9 more
      Jan 27, 2023

      Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

      Not yet recruiting
      • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
      • Ivosidenib 500mg
      • Placebo
      • (no location specified)
      Nov 7, 2023

      IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

      Not yet recruiting
      • IDH1-mutant Cholangiocarcinoma
      • (no location specified)
      Jun 29, 2023

      Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

      Active, not recruiting
      • Acute Myeloid Leukemia
      • +3 more
      • Edmonton, Alberta, Canada
      • +1 more
      Jan 31, 2023

      Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States

      Recruiting
      • Accelerated/Blast-phase Myeloproliferative Neoplasm
      • +2 more
      • Scottsdale, Arizona
      • +10 more
      May 9, 2022

      Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

      Recruiting
      • Leukemia
      • +2 more
      • Enasidenib mesylat dose escalation
      • Palo Alto, California
        Stanford Cancer Institute
      May 12, 2022

      Glioma Trial in United States (AG881)

      Active, not recruiting
      • Glioma
      • Los Angeles, California
      • +8 more
      May 16, 2022

      Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)

      Recruiting
      • Advanced Solid Tumor
      • +2 more
      • ivosidenib and nivolumab
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Mar 14, 2022

      Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)

      Recruiting
      • Isocitrate Dehydrogenase Gene Mutation
      • Santa Monica, California
      • +8 more
      Feb 22, 2022

      Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)

      Recruiting
      • Recurrent Glioma
      • +4 more
      • Hong Kong, Hong Kong
        Department of Clinical Oncology
      Aug 19, 2021

      Molecular Pathology Research Project of Glioma

      Completed
      • Glioma, Malignant
      • Detection of IDH and TERT mutation
      • Shanghai, Jingan District, China
        Huashan Hospital
      Mar 9, 2022

      Non Invasive IDentification of Gliomas With IDH1 Mutation

      Completed
      • Non Invasive Diagnosis of Glioma
        • Paris, Sélectionner..., France
          GH Pitié-Salpêtrière, 47 Bd de l'Hopital,
        Aug 25, 2021

        IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)

        Active, not recruiting
        • IDH1 Mutation Myeloid Neoplasms
        • Baltimore, Maryland
        • +3 more
        Oct 25, 2021